End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
780,000 KRW | -1.27% | -1.27% | +2.63% |
Apr. 25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
Apr. 25 | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.63% | 40.42B | |
-4.66% | 87.53B | |
-21.76% | 29.48B | |
+55.89% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+4.34% | 8.75B | |
-8.42% | 7.99B |
- Stock Market
- Equities
- A207940 Stock
- News Samsung Biologics Co.,Ltd.
- Samsung Biologics : Enzolytics Sign Deal for Anti-HIV, Anti-COVID-19 Monoclonal Antibody Therapies